REFERENCES
- Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931–940, [INFOTRIEVE], [CSA]
- Shokouh-Amiri MH, Egidi MF, Lo A, et al. The importance of early prevention of renal dysfunction in liver transplant recipients. Transplant Proc 2001; 33: 1399–1400, [INFOTRIEVE], [CSA], [CROSSREF]
- Velidedeoglu E, Crawford MD, Desai NM, et al. Predictors of late kidney dysfunction post-liver transplantation. Transplant Proc 2002; 34: 3315–3316, [INFOTRIEVE], [CSA], [CROSSREF]
- Gonwa TA, Mai ML, Melton LB, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001; 72: 1934–1939, [INFOTRIEVE], [CSA], [CROSSREF]
- Moreno JM, Cuervas-Mons V, Rubio E, et al. Chronic renal dysfunction after liver transplantation in adult patients: prevalence, risk factors, and impact on mortality. Transplant Proc 2003; 35: 1907–1908, [INFOTRIEVE], [CSA], [CROSSREF]
- Gonwa TA, Klintmalm GB, Levy M, Jennings LS, Goldstein RM, Husberg BS. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995; 59: 361–365, [INFOTRIEVE], [CSA]
- Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation 1998; 66: 59–67, [INFOTRIEVE], [CSA], [CROSSREF]
- Eknoyan G. Meeting the challenges of the new K/DOQI guidelines. Am J Kidney Dis 2003; 41: 3–10, [INFOTRIEVE], [CSA], [CROSSREF]
- Poplawski S, Gonwa T, Goldstein R, Husberg B, Klintmalm G. Long-term nephrotoxicity in liver transplantation. Transplant Proc 1989; 21: 2469–2471, [INFOTRIEVE], [CSA]
- Gayowski T, Singh N, Keyes L, et al. Late-onset renal failure after liver transplantation: role of post-transplant alcohol use. Transplantation 2000; 69: 383–388, [INFOTRIEVE], [CSA], [CROSSREF]
- Gonwa TA, Poplawski SC, Husberg BS, Nery JR, Klintmalm GB. Cyclosporine nephrotoxicity in orthotopic liver transplantation. Transplant Proc 1988; 20: 401–404, [INFOTRIEVE], [CSA]
- Wilkinson AH, Cohen DJ. Renal failure in the recipients of nonrenal solid organ transplants. J Am Soc Nephrol 1999; 10: 1136–1144, [INFOTRIEVE], [CSA]
- Gonwa TA, Mai ML, Melton LB, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001; 72: 1934–1939, [INFOTRIEVE], [CSA], [CROSSREF]
- Gonwa TA, Mai ML, Klintmalm GB. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 2563–2565, [INFOTRIEVE], [CSA], [CROSSREF]
- Iwatsuki S, Esquivel CO, Klintmalm GB, Gordon RD, Shaw BW, Jr., Starzl TE. Nephrotoxicity of cyclosporine in liver transplantation. Transplant Proc 1985; 17: 191–195, [INFOTRIEVE], [CSA]
- Puschett JB, Greenberg A, Holley J, McCauley J. The spectrum of ciclosporin nephrotoxicity. Am J Nephrol 1990; 10: 296–309, [INFOTRIEVE], [CSA]
- Yoshida EM, Marotta PJ, Greig PD, et al. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Liver Transpl 2005; 11: 1064–1072, [INFOTRIEVE], [CSA], [CROSSREF]
- Soccal PM, Gasche Y, Favre H, Spiliopoulos A, Nicod LP. Improvement of drug- induced chronic renal failure in lung transplantation. Transplantation 1999; 68: 164–165, [INFOTRIEVE], [CSA], [CROSSREF]
- Aleksic I, Baryalei M, Busch T, et al. Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine. Transplantation 2000; 69: 1586–1590, [INFOTRIEVE], [CSA], [CROSSREF]
- Schrama YC, Joles JA, van Tol A, Boer P, Koomans HA, Hene RJ. Conversion to mycophenolate mofetil in conjunction with stepwise withdrawal of cyclosporine in stable renal transplant recipients. Transplantation 2000; 69: 376–383, [INFOTRIEVE], [CSA], [CROSSREF]
- Chan CY, DasGupta K, Baker AL. Cyclosporin A: drug discontinuation for the management of long-term toxicity after liver transplantation. Hepatology 1996; 24: 1085–1089, [INFOTRIEVE], [CSA]
- Sandborn WJ, Hay JE, Porayko MK, et al. Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. Hepatology 1994; 19: 925–932, [INFOTRIEVE], [CSA], [CROSSREF]
- Detry O, De Roover A, Honore P, Delwaide J, Jacquet N, Meurisse M. Mycophenolate mofetil monotherapy in stable liver transplant recipients with progressive renal failure. Transplant Proc 2002; 34: 782–783, [INFOTRIEVE], [CSA], [CROSSREF]
- Neau-Cransac M, Morel D, Bernard PH, et al. Renal failure after liver transplantation: outcome after calcineurin inhibitor withdrawal. Clin Transplant 2002; 16: 368–373, [INFOTRIEVE], [CSA], [CROSSREF]
- Barkmann A, Nashan B, Schmidt HH, et al. Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil. Transplantation 2000; 69: 1886–1890, [INFOTRIEVE], [CSA], [CROSSREF]
- Moreno Planas JM, Cuervas-Mons Martinez V, Rubio Gonzalez E, et al. Mycophenolate mofetil can be used as monotherapy late after liver transplantation. Am J Transplant 2004; 4: 1650–1655, [INFOTRIEVE], [CSA], [CROSSREF]
- Papatheodoridis GV, O'Beirne J, Mistry P, Davidson B, Rolles K, Burroughs AK. Mycophenolate mofetil monotherapy in stable liver transplant patients with cyclosporine-induced renal impairment: a preliminary report. Transplantation 1999; 68: 155–157, [INFOTRIEVE], [CSA], [CROSSREF]
- Schlitt HJ, Barkmann A, Boker KH, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 2001; 357: 587–591, [INFOTRIEVE], [CSA], [CROSSREF]
- Pruvot F, Hazzan M, Roumilhac D, et al. Improvement of severe chronic renal dysfunction by replacement of anticalcineurins with mycophenolate mofetil in long term liver transplant recipients. Am J Transplant 2003; 3(suppl 5)376, [CSA]
- Cantarovich M, Tzimas GN, Barkun J, Deschenes M, Alpert E, Tchervenkov J. Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction. Transplantation 2003; 76: 98–102, [INFOTRIEVE], [CSA], [CROSSREF]
- Raimondo ML, Dagher L, Papatheodoridis GV, et al. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation 2003; 75: 186–190, [INFOTRIEVE], [CSA], [CROSSREF]
- Citterlo F, Scata MC, Violi P, et al. Rapid conversion to sirolimus for chronic progressive deterioration of the renal function in kidney allograft recipients. Transplant Proc 2003; 35: 1292–1294, [INFOTRIEVE], [CSA], [CROSSREF]
- Mota A, Arias M, Taskinen EI, et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at three years. Am J Transplant 2004; 4: 953–961, [INFOTRIEVE], [CSA], [CROSSREF]
- Groetzner J, Kaczmarek I, Meiser B, Muller M, Daebritz S, Reichart B. Sirolimus and mycophenolate mofetil as calcineurin inhibitor-free immunosuppression in a cardiac transplant patient with chronic renal failure. J Heart Lung Transplant 2004; 23: 770–773, [INFOTRIEVE], [CSA], [CROSSREF]
- Nair S, Eason J, Loss G. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transplant 2003; 9: 126–129, [CSA], [CROSSREF]
- Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transplant 2003; 9: 1079–1085, [CSA], [CROSSREF]
- Johnson RJ, Wilson R, Yamabe H, et al. Renal manifestations of hepatitis C virus infection. Kidney Int 1994; 46: 1255–1263, [INFOTRIEVE], [CSA]
- Stehman-Breen C, Willson R, Alpers CE, Gretch D, Johnson RJ. Hepatitis C virus-associated glomerulonephritis. Curr Opin Nephrol Hypertens 1995; 4: 287–294, [INFOTRIEVE], [CSA]